Liliang Xia

1.7k total citations · 2 hit papers
30 papers, 1.2k citations indexed

About

Liliang Xia is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Liliang Xia has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 12 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in Liliang Xia's work include Cancer Immunotherapy and Biomarkers (19 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (6 papers). Liliang Xia is often cited by papers focused on Cancer Immunotherapy and Biomarkers (19 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (6 papers). Liliang Xia collaborates with scholars based in China, Thailand and Hong Kong. Liliang Xia's co-authors include Ying Wang, Yuanyong Liu, Shun Lü, Yi Yang, Chengcheng Yao, Yueping Jin, Yongqiang Zhu, Hui Dong, Yan Shen and Huajun Zheng and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Science Translational Medicine.

In The Last Decade

Liliang Xia

29 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC

2019 396 citations Yueping Jin, Hui Dong et al. Journal of Thoracic Oncology profile →
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions

2019 281 citations Liliang Xia, Yuanyong Liu et al. The Oncologist profile →

Peers

Countries citing papers authored by Liliang Xia

Since Specialization

Citations

This map shows the geographic impact of Liliang Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liliang Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liliang Xia more than expected).

Fields of papers citing papers by Liliang Xia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liliang Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liliang Xia. The network helps show where Liliang Xia may publish in the future.

Co-authorship network of co-authors of Liliang Xia

This figure shows the co-authorship network connecting the top 25 collaborators of Liliang Xia. A scholar is included among the top collaborators of Liliang Xia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liliang Xia. Liliang Xia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single-cell spatial proteomics of non-relapse small cell lung cancer identifies tumor microenvironment determinants of survival 2025 ·Cell Biology and Toxicology ·Yin Li, Liliang Xia, Hui Wang, Xinghao Ai, (unknown), Qingquan Luo, Yuchen Han, Shun Lu, Xinghua Cheng	0
2	The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect 2024 ·Cancer Letters ·Liliang Xia, (unknown), Ying Wang, Shun Lü	18
3	EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment 2024 ·Lung Cancer ·(unknown), Liliang Xia, (unknown), (unknown), Jing Wang, Xing Li, Yongfeng Yu, Ziming Li, (unknown), Guanshan Zhu, Shun Lü	5
4	PTPRT loss enhances anti–PD-1 therapy efficacy by regulation of STING pathway in non–small cell lung cancer 2024 ·Science Translational Medicine ·Zhuo Chen, Wenxiang Ji, (unknown), (unknown), (unknown), Fan Li, (unknown), (unknown), Liliang Xia, (unknown), (unknown), (unknown), (unknown), Alice S.T. Wong, Shun Lü, Weiliang Xia	9
5	EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer 2024 ·Journal of Translational Medicine ·(unknown), (unknown), Yongfeng Yu, Ziming Li, Yi Yang, Liliang Xia, Shun Lü	10
6	Accumulation of branched-chain amino acids reprograms glucose metabolism in CD8+ T cells with enhanced effector function and anti-tumor response 2023 ·Cell Reports ·(unknown), (unknown), Yi Yang, Haiyan Zhou, (unknown), (unknown), Liliang Xia, Ping Ji, Yingying Chen, Guoqing Zhang, Haipeng Sun, Shun Lü, Chen Yang, Ying Wang	48
7	A 3D Ex Vivo Tumor‐Immune Coculture System Mimicking In Vivo Tumor Environmental Stress on CD8+ T Cells Exhaustion 2023 ·Advanced Biology ·(unknown), Xiaomin Niu, Liliang Xia, Yingying Chen, Zhen Wang, Hui Wang, (unknown), Wenguo Cui, Ying Wang, Shun Lü	3
8	Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer 2021 ·Science China Life Sciences ·Liliang Xia, Hui Wang, Mingjiao Sun, Yi Yang, Chengcheng Yao, Sheng He, (unknown), (unknown), (unknown), (unknown), Zhiwei Chen, Qiong Zhao, Hong Li, Shun Lü, Ying Wang	18
9	Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer 2021 ·Frontiers in Immunology ·Liliang Xia, (unknown), (unknown), Yi Yang, (unknown), (unknown), (unknown), Shun Zhang, Wenfeng Li, (unknown), Hongyan Chen, Ziming Li, Jin‐Ji Yang, Shun Lü, Ying Wang	25
10	A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer. 2021 ·PubMed ·Yi Yang, Jiancheng Yang, Lan Shen, Jiajun Chen, Liliang Xia, Bingbing Ni, Liang Ge, Ying Wang, Shun Lü	60
11	Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma 2021 ·Translational Oncology ·Lin Gao, Liliang Xia, Wenxiang Ji, Yanshuang Zhang, Weiliang Xia, Shun Lü	30
12	Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation 2020 ·Frontiers in Immunology ·Chen Wang, Yu Ding, Yuanyong Liu, Qingchen Zhang, Shiqiang Xu, Liliang Xia, (unknown), Shujun Wang, Ping Ji, Weiren Huang, Guoping Zhao, Zhiwei Cao, Haibo Shen, Ying Wang	7
13	PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions breakdown → 2019 ·The Oncologist ·Liliang Xia, Yuanyong Liu, Ying Wang	281
14	The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC breakdown → 2019 ·Journal of Thoracic Oncology ·Yueping Jin, Hui Dong, Liliang Xia, Yi Yang, Yongqiang Zhu, Yan Shen, Huajun Zheng, Chengcheng Yao, Ying Wang, Shun Lü	396
15	PD-1 blockade augments humoral immunity through ICOS-mediated CD4+ T cell instruction 2018 ·International Immunopharmacology ·Meiyu Zhang, Liliang Xia, Yi Yang, Shuai Liu, Ping Ji, Shujun Wang, Yingying Chen, Zhiduo Liu, Yi Zhang, Shun Lü, Ying Wang	17
16	Identification of HLA-A2-Restricted Mycobacterial Lipoprotein Z Peptides Recognized by T CellsFrom Patients With ActiveTuberculosis Infection 2018 ·Frontiers in Microbiology ·Yuanyong Liu, Wei Sha, Shiqiang Xu, (unknown), Liliang Xia, Ping Ji, Shujun Wang, Guoping Zhao, Xiao Zhang, Yingying Chen, Ying Wang	3
17	Human dCTP pyrophosphatase 1 promotes breast cancer cell growth and stemness through the modulation on 5-methyl-dCTP metabolism and global hypomethylation 2015 ·Oncogenesis ·(unknown), Liliang Xia, Ping Ji, (unknown), Zhimin Huang, Lili Zhu, Jian Zhang, (unknown), Guoping Zhao, (unknown), Yanwen Zhang, (unknown)	38
18	A High-Affinity CDR-Grafted Antibody against Influenza A H5N1 Viruses Recognizes a Conserved Epitope of H5 Hemagglutinin 2014 ·PLoS ONE ·(unknown), Liliang Xia, Jingfang Wang, (unknown), (unknown), (unknown), Yating Cheng, (unknown), (unknown), Qinghua Zhang, Guoping Zhao, Ying Wáng	3
19	Development of VHH Antibodies against Dengue Virus Type 2 NS1 and Comparison with Monoclonal Antibodies for Use in Immunological Diagnosis 2014 ·PLoS ONE ·(unknown), Haiying Wang, (unknown), Liliang Xia, Ying Wang, Wei Ye, Jufang Wang, Xiaoning Wang	41
20	Complete Genome Sequence of an Acinetobacter Strain Harboring the NDM-1 Gene 2013 ·Genome Announcements ·Yang Sun, Yang Song, Hongbin Song, Jun Liu, Pengzhi Wang, Shaofu Qiu, Shuo Chen, Lingwei Zhu, (unknown), Zhongqiang Wang, Nan Liu, Liliang Xia, Weijun Chen, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact